Details

Autor(en) / Beteiligte

• Zhou, Hu
• Zhou, Jianfeng
• Wu, Depei
• Ma, Liping
• Du, Xin
• Niu, Ting
• Yang, Renchi
• Liu, Jing
• Zhang, Feng
• Shi, Qingzhi
• Wang, Xiuli
• Jing, Hongmei
• Li, Junmin
• Wang, Xin
• Cui, Zhongguang
• Zhou, Zeping
• Hou, Ming
• Shao, Zonghong
• Jin, Jie
• Li, Wenqian
• Ren, Hanyun
• Hu, Jianda
• Shen, Jianliang
• Liu, Li
• Zeng, Yun
• Zhou, Jin
• Liu, Xin
• Shen, Yunfeng
• Ding, Kai
• Taira, Tadaaki
• Cai, Huacong
• Zhao, Yongqiang

Titel

Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China

Ist Teil von

• Research and practice in thrombosis and haemostasis, 2023-07, Vol.7 (5), p.100192-100192, Article 100192

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Multiple trials have confirmed that romiplostim could increase platelet count in individuals with primary immune thrombocytopenia (ITP), but no related study has assessed Chinese patients. To assess the effectiveness of romiplostim as a second-line treatment of persistent or chronic ITP in Chinese adults. This phase III multicenter, randomized, placebo-controlled, double-blind, then open-label clinical trial (NCT02868099, CTR20150395) was conducted at 28 investigational sites in China. The patients were randomly assigned (3:1) to romiplostim (starting and maximum doses of 1 and 10 μg/kg, respectively) or placebo for 9 weeks (double-blind period), followed by the open-label period (both groups administered romiplostim) to week 22. The primary endpoint was the time (in weeks) during which platelet counts were ≥50 × 109/L in the double-blind period. In this study, 202 patients (romiplostim, n = 151; placebo, n = 51) started the treatment. The median (range) numbers of weeks with platelet response after 6 weeks of treatment were 2 (0-6) and 0 (0-2) in patients administered romiplostim and placebo, respectively (P < .001). During the double-blind period, the proportions of patients with treatment-emergent adverse events were comparable between the romiplostim and placebo groups (82.8% vs 82.4%). The treatment-emergent adverse event with ≥10% difference in incidence between these 2 groups was injection site bleeding (1.3% vs 11.8%). Romiplostim significantly increased the time with maintained platelet response in patients with persistent or chronic ITP in comparison with placebo. No new safety signal was observed. ClinicalTrials.gov, NCT02868099. www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml, CTR20150395 •Evidence on romiplostim in the immune thrombocytopenia (ITP) population in China is needed.•This was a phase III multicenter, randomized, placebo-controlled clinical study.•Longer duration of platelet response was demonstrated in ITP patients treated with Romiplostim.•No new safety signal of romiplostim was observed.